Dr. David R. Spigel
Medical OncologistMedical oncologist Dr. David Spigel is the chief scientific officer at the Sarah Cannon Research Institute and a member of Tennessee Oncology, one of America’s largest community based groups of cancer-care specialists.
-
Tennessee Oncology Nashville, Tennessee (TN)
-
Expertise:Clinical Trials
Hematology -
Speciality:Medical Oncology -
Gender:Male -
Language:English -
Primary Location:Tennessee Oncology
Get to Know Dr. David Spigel
Dr. David Spigel is a medical oncologist and chief scientific officer at the Sarah Cannon Research Institute, overseeing the innovative clinical trials that are advancing the treatment of malignant mesothelioma and many other cancers.
Spigel, who specializes in hematology, also is part of the community based Tennessee Oncology group in Nashville, where he sees patients at the TriStar Centennial Medical Center.
He has played a key role in the recent development of immunotherapy and other targeted medicines being developed at Sarah Cannon.
Spigel works closely with other cancer research leaders, along with pharmaceutical and biotech companies, to bring the latest advances from the laboratory into the clinic.
Although he handles all adult malignancies, he has special clinical interest in thoracic cancers, including lung cancer and mesothelioma. He also treats Hodgkin’s lymphoma, multiple myeloma and esophageal cancer.
Specialties of Dr. David Spigel
- Pleural mesothelioma
- Lung cancer
- Adult malignancies
- Clinical trials
- Cancer research
- Hematology
Dr. David Spigel’s Experience and Medical Education
- Tennessee Oncology
- Sarah Cannon Research Institute
- Dana-Farber Cancer Institute (Fellowship)
- Indiana University Medical Center (Residency)
- University of Tennessee College of Medicine
Awards and Other Recognitions
- Patient Safety Excellence Award
- Medical oncology board certified
- American Society of Clinical Oncology (Member)
- American College of Physicians (Member)
Mesothelioma Clinical Trials Under David Spigel, M.D.
- A phase I/II clinical trial to establish dosage levels and overall response rate using genetically engineered T-cells for patients with pleural mesothelioma and lung cancer expressing high levels of mesothelin.
- Phase I/II clinical trial studying the use of INCB001158 as a single agent and in combination with an immune checkpoint inhibitor for patients with metastatic solid tumors, including mesothelioma.
- A phase Ib/II clinical trial studying rebastinib in combination with carboplatin chemotherapy to assess safety and efficacy for patients with advanced or metastatic solid tumors, including mesothelioma cancer.
Publications of Dr. David Spigel
- Horn, L., Spigel, D. et al. (2017, October 12). Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057). Journal of Clinical Oncology.
- Spigel, D. (2013, November 10). Randomized Phase II Trial of Onartuzumab in Combination With Erlotinib in Patients With Advanced Non-Small-Cell Lung Cancer. Journal of Clinical Oncology
Watch Our Free Mesothelioma Webinars
Find Active Mesothelioma Clinical Trials
Mesothelioma Trust Funds
